Beckman Coulter, Inc. and Aviv Biomedical, Inc. announced an agreement authorizing Aviv to sell and install its Fluorescence Detection System on fielded Beckman Coulter ProteomeLab XL-A, XL-I analytical ultracentrifuges. The ProteomeLab XL-A, XL-I provides analysis of heterogeneity, stoichiometry, interacting/self-associating systems and molecular conformation. The system measures proteins and other macromolecules as interacting elements in solution (rather than in isolation, diluted, or bound to a substrate). The Aviv Analytical Ultracentrifuge Fluorescence Detection System (AU-FDS) offers a complementary approach to measuring molecular interaction and aggregation behavior.
The fluorescent labeling of a single component in a mixture enables investigators to validate drug lead efficacy by confirming that it only binds to the desired substrate. With the new AU-FDS accessory, the XL-A, XL-I’s core absorbance/interference detection can be run sequentially with the fluorescence optical system. In addition to rigorous characterization, this technology measures relative changes in the distribution of molecular weights.
This article was published in Drug Discovery & Development magazine: Vol. 11, No. 4, April, 2008, pp. 9.
Filed Under: Drug Discovery